Clinical trials: SARS-COV-2 Infection
COVID-19
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
To explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection
- Trial name
- NCT04679350
- Testing
- hzVSF-v13
- Where
- 3 sites in South Korea
- Volunteers
- 1 people
- Sponsor
- ImmuneMed, Inc.
SARS CoV 2 Infection
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study…
- Trial name
- NCT06283459
- Testing
- IMNN-101
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Imunon
COVID-19
Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag ULTRA Test
Performance of the LumiraDx SARS-CoV-2 Ag ULTRA assay will be assessed by comparison to a reference method
- Trial name
- ASPIRE-2 (NCT05506618)
- Testing
- Nasal Swab, Nasopharyngeal swab
- Where
- 6 sites in United States
- Volunteers
- 758 people, healthy volunteers welcome
- Sponsor
- LumiraDx UK Limited
COVID-19
Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients
The recent COVID-19 outbreak has put the health care workers on the frontline to interact and provide support to the patients. Based on previous disease outbreak-associated studies, it is evident that these individuals are at a…
- Trial name
- BADS-PTSD (NCT04473118)
- Testing
- Survey
- Where
- Qatar
- Volunteers
- 25,000 people
- Sponsor
- Hamad Medical Corporation
SARS-CoV-2 Infections
A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults
This is a Phase 1, open-label, randomized, 2-period, 2-sequence, cross-over study to estimate the effect of ibuzatrelvir on the PK of dabigatran, a P-gp substrate, in healthy adult participants.
- Trial name
- NCT06693518
- Testing
- Treatment B, Treatment A
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19
Protocol bacTRL-Spike-1 will be the first-in-human study of bacTRL-Spike, and the first-in-human use of orally delivered bacTRL.
- Trial name
- NCT04334980
- Testing
- bacTRL-Spike
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Symvivo Corporation
COVID-19
Beat COVID-19 - Observational Trial
JUPITER is an observational study protocol that aims to understand factors that can help prevent/mitigate the spread of COVID-19 and understand factors that help reduce disease progression in patients with COVID-19.
- Trial name
- JUPITER (NCT04337762)
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Beat COVID LLC
Covid19
Saliva-based COVID-19 DNA Aptamer Test
This study aims to conduct formative usability and internal validation of the COVID-19 rapid diagnostic test tool based on DNA aptamers, involving 200 patients to assess aspects of experimental setup, testing center, testing kit…
- Trial name
- NCT04974203
- Testing
- AptameX
- Where
- Indonesia
- Volunteers
- 200 people
- Sponsor
- Achiko AG
COVID-19
Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
The primary objectives of the study are: To assess the safety profile of the study vaccines in each study intervention group. To assess the neutralizing antibody profile after primary series vaccination in SARS-CoV-2-naïve…
- Trial name
- NCT04762680
- Testing
- SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 3,159 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205096
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Coronavirus
A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
This is a randomized controlled trial to evaluate the efficacy and safety of itolizumab in subjects hospitalized with COVID-19.
- Trial name
- EQUINOX (NCT04605926)
- Testing
- EQ001
- Where
- Colombia
- Sponsor
- Biocon Limited
COVID-19, SARS-CoV2 Infection
COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests
The aim of the COVAG study (Covid-19 Antigen study) is to assess the diagnostic efficacy of two of the most used rapid antigen tests (Roche \& Abbott).
- Conditions
- COVID-19, SARS-CoV2 Infection, SARS (Disease)
- Trial name
- COVAG (NCT05074017)
- Testing
- 3 nasopharyngeal swab
- Where
- 2 sites in Germany
- Volunteers
- 2,222 people, healthy volunteers welcome
- Sponsor
- Synlab Holding Deutschland GmbH
COVID-19
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.
- Trial name
- PROVENT (NCT04625725)
- Testing
- AZD7442
- Where
- 89 sites in United States, Belgium and 3 more
- Volunteers
- 5,197 people
- Sponsor
- AstraZeneca
COVID-19
Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
To evaluate the safety and immunogenicity of the COVID-19 mRNA vaccine in people aged 18 years and older, 80 participants will be enrolled and divided into two groups: low- and high-dose groups.
- Trial name
- NCT05373485
- Testing
- COVID-19 mRNA vaccine
- Where
- 3 sites in China
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Healthy People
Safety of UFRJvac, Trivalent COVID-19 Vaccine
Phase I study to evaluate the safety and immunogenicity of the vaccine booster with the trivalent UFRJvac COVID-19 vaccine.
- Trial name
- UFRJvac-1 (NCT06303635)
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
COVID-19
Dose-finding Study for AdimrSC-2f Vaccine
AdimrSC-2f is a subunit protein-based vaccine produced using the baculovirus insect cells manufacturing process to prevent Coronavirus disease 2019 (COVID-19).
- Trial name
- NCT05104489
- Testing
- AdimrSC-2f
- Where
- Indonesia
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
COVID-19, Influenza
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
- Trial name
- NCT06694389
- Testing
- mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine
- Where
- 44 sites in Japan, South Korea and 1 more
- Volunteers
- 2,457 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada
This study is a phase I /II adaptive clinical trial to evaluate the safety, tolerability and the Immunogenicity of Ad5-nCoV in healthy adults from 18 to <55 and 65 to <85 years of age，with the randomized, observer-blind…
- Trial name
- NCT04398147
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- Canada
- Volunteers
- 696 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Covid19
A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated
This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged…
- Trial name
- COVID-19 (NCT04863638)
- Testing
- 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Covid 19
Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.
This study will explore the contribution of CBD oral drops in persons experiencing symptoms of Post Acute COVID Syndrome or "PACS".
- Trial name
- "BAC-PAC" (NCT04828668)
- Testing
- Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Endourage, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.